Navigation Links
Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting

etaxel with prednisone in patients with chemotherapy-naive metastatic hormone refractory prostate cancer Roman L, Karlov P, Kaprin A, Gladkov O, Breitz H.

About Picoplatin

Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. It is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Poniard is evaluating intravenous picoplatin in an ongoing Phase 2 clinical trial in SCLC and in Phase 1/2 clinical trials in colorectal and

hormone-refractory prostate cancers. On May 1, 2007, the Company announced treatment of the first patient in its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of intravenous picoplatin in SCLC, which is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Poniard received orphan drug designation from the U.S. Food and Drug Administration in November 2005 for picoplatin for the treatment of SCLC. Poniard also is evaluating an oral formulation of picoplatin in a Phase 1 clinical trial.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. The Company's lead drug product candidate is picoplatin, which is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancers. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:10/8/2008)...atments for Spinal Cord, Other Nerve,Injuries -, ...protein that enables,nerve cells to communicate wi...developing nervous system. Research into how that ...rve cells may provide a basis for eventual,treatme...ous system,including spinal cord injury., "This ...
(Date:10/8/2008)...continued and Headcount to be Reduced, Summary: Ge...; Zanolimumab Program to be Discontinued and the ... Employees, COPENHAGEN, October 8 /P...unced today that it is discontinuing development o...sult of a portfolio review and,assessment of the o...
(Date:10/8/2008)...TAXUS(R) Element(TM) Platinum Chromium ... /- Boston Scientific,Corpo...ompleted enrollment in,the PERSEUS trial, designed...R) Element(TM) paclitaxel-eluting coronary stent. ...,500 patients at 100 U.S. and,international center...
(Date:10/8/2008)... -- Vical Incorporated (Nasdaq: VICL ),today is p...al data,demonstrating that the company,s Vaxfectin... protein-based infectious disease vaccines and,pep...m.D., Ph.D., Vical,s,Senior Vice President of Prod...esday, October 8, at the World Vaccine Congress (L...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 2Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 3Genmab A/S - Company Announcement: Genmab Reports Results of Portfolio 4Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 1Saving Lives of Florida Residents Who Develop Skin Cancer Each Year 3A The Key is Early Detection and Treatment 252 2CABI helps phase out dangerous pesticide in EU 356 1CABI helps phase out dangerous pesticide in EU 356 2Microbiotic technology developed for microinjection of zebrafish embryos 1069 1Family Dinners Shape Healthier Eating Habits 1065 1
...--May 15, 2007 - Synthetic Blood,International, In...,a statistical analysis of its Phase IIa study wit...ury. In line with preliminary,study results announ...d that the primary endpoint of increasing patients... met. Data also show a,decrease in patient glucose...
... 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SL...r-initiated trials related to the Company,s produc...2007, which will be,held May 19-24, 2007. Digestiv...prestigious meeting in the world for the GI,profes...ysicians,researchers and academics from around th...
Other Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
(Date:10/10/2008)...10 /PRNewswire-FirstCall/ -- Hologic, Inc.,(Nasdaq...upplier of premium,diagnostics, medical imaging sy...he healthcare needs of women, today announced plan...erating results on Tuesday, November 11,2008 afte...anagement will,host a conference call on Tuesday, ...
(Date:10/10/2008)... Upon the completion of a highly successful CIO Fi...roudly announces their next business technology ga...ology executives in healthcare. CDM Media has conf...-12, 2009 at the Four Seasons Resort in Scottsdale...EB) October 11, 2008 -- Upon the completion of a h...
(Date:10/10/2008)... 10 /PRNewswire/ -- NuView Life Sciences Inc.,(NuV... Sciences Inc.,(Trace), including operations of th...lities in Denton, Texas. The Trace facility produc...nd Thallium-201 used in,molecular imaging and nucl... stated that "We are confident that by improving o...
(Date:10/10/2008)...Calif., Oct. 10 /PRNewswire/ -- A senior citizen,s...ountains in a small,plane. The high-flying adventu.... The thrill came from a last-wish program through...nior Living, where Heden was a patient.,Called Go ...it has helped,many realize a special activity at t...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2Health News:Deck of Cards is More Than a Game: Integral in Silverado Hospice Care 2
...ork-Presbyterian Hospital/Weill Cornell Medical Ce...nts the ability of an antibody to directly target ...ing healthy tissues unharmed. The Phase I clinica..., targeted to the prostate specific membrane antig...
...y 40% of the doctors in one Russian city have late...ho work in TB clinics. The research has been publi...oblem worldwide. Russia is one country where it is... third of the world's population are infected with...
... standard breast cancer therapy drug tamoxifen, to...s by almost one-fifths. Publishing their finding... Dr. Francesco Boccardo of the National Cancer Res... changing treatments tracks to exemestane after 2 ...
...r from persistent iron overload has been cleared. ...um. Patients suffering from a rare genetic condit...se need regular blood transfusions. Generally thes... at nights by needle and pump which lasts for arou...
Other Medicine News:Health News:First Treatment to Directly Target Tumor Blood Supply 2Health News:First Treatment to Directly Target Tumor Blood Supply 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2
...dy (IgG) Test is a semiquantitative enzyme immunoa...cant IgG antibodies to M. pneumoniae between acute...should not be used for specimens found reactive wi... Test and is not intended for qualitative (one spe...
...unoassay (EIA) that detects IgG antibodies to Epst...arr early nuclear antigen (EBV-EBNA), cytomegalovi...n with Mono-M Test it is an aid in the serodiagnos...ve serodiagnosis of CMV or Toxoplasma mononucleosi...
The ImmunoDOT TORCH Test is an enzyme immunoassay (EIA) procedure intended for determining the presence of antibodies to Toxoplasma gondii, rubella virus, cytomegalovirus and herpes simplex virus in
...e enzyme immunoassays (EIA) for the presumptive de... IgM, respectively) in serum. Equivocal or positiv...with a standardized western blot procedure. These ...ical diagnosis of B. burgdorferi infection (Lyme d...
Medicine Products: